RT Journal Article
T1 Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy.
A1 Bieback, Karen
A1 Fernandez-Muñoz, Beatriz
A1 Pati, Shibani
A1 Schäfer, Richard
K1 Blood Platelets
K1 Blood Safety
K1 Fetal Blood
K1 Quality Control
K1 Unidad de Producción y Reprogramación Celular (UPRC)
K1 Laboratorio Andaluz de Reprogramación Celular (LARCEL)
K1 Iniciativa Andaluza de Terapias Avanzadas, Sevilla
AB Cell therapeutics are emerging as a viable modality to treat challenging diseases such as cancer, organ degeneration, or (auto)immune diseases resulting in an increased demand for their large-scale, high-quality production. Currently, fetal bovine serum (FBS) is the most widely used growth factor supplement for the expansion of human cell therapy products. However, there has been a strong impetus from regulatory agencies and biomedical professionals in the field to develop methods for cell expansion that do not utilize animal products in their production process.1 Human platelet lysate (hPL) has been identified as a possible growth supplement contender—rich in growth factors and produced in most cases from expired platelets (PLTs)—that can be used to replace FBS.
PB Wiley-Blackwell Publishing, Inc.
SN 0041-1132
YR 2019
FD 2019-11-06
LK http://hdl.handle.net/10668/14393
UL http://hdl.handle.net/10668/14393
LA en
NO Bieback K, Fernandez-Muñoz B, Pati S, Schäfer R. Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy. Transfusion. 2019 Nov;59(11):3448-3460.
DS RISalud
RD Apr 7, 2025